Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
The product will be manufactured at Lupin's facility in Nagpur, India.
This combination medicine is used to treat high blood pressure (hypertension).
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
